Skip to content
Back to Blog
Bio
2026-07-277 min read13

Attracting 2026 H2 VC Capital Amid Korea's Oncology-Immunology Investment Concentration

With over USD 3.9 billion of H1 2026 Korean bio VC funding concentrated in oncology and immunology, this article outlines practical fundraising strategies for non-oncology biotech SMEs amid new policy changes extending venture fund terms from 3 to 5 years.

KITIM Consulting Team

H1 2026 Korean Bio Investment Trends: The Oncology-Immunology Concentration

In the first half of 2026, venture capital invested in Korea's biohealth sector surpassed USD 9 billion, but the composition reveals a stark imbalance: more than USD 3.9 billion of that total flowed into oncology and immunology drug developers alone. The global frenzy around antibody-drug conjugates (ADCs), bispecific antibodies, and cell therapy licensing deals has directly shaped domestic investor sentiment.

The problem is that this concentration has made fundraising markedly harder for biotech ventures working in non-oncology areas — metabolic disease, neurodegenerative disease, rare disease, and infectious disease pipelines. Startups increasingly face the question "do you have a plan to expand into oncology indications?" during investment rounds, and non-oncology pipelines are frequently valued lower than oncology assets at comparable clinical stages. As a result, for non-oncology biotech companies, a clear, persuasive IR narrative on "why invest in this pipeline now" has become just as critical as the underlying science.

Policy Shift: Venture Investment Fund Minimum Term Extended from 3 to 5 Years (Effective July 1, 2026)

Against this backdrop, an amended regulation took effect on July 1, 2026, extending the minimum duration of individual investment associations and venture investment associations from 3 years to 5 years. Since biotech drug development typically takes 3 to 5 years just to reach Phase 1 clinical entry, the previous 3-year fund structure created a structural mismatch — funds often faced exit pressure before clinical results were even available. The extension aligns fund lifecycles with biotech's actual development timeline, laying the groundwork for more patient capital to enter the sector.

Alongside this, new policy financing was introduced specifically for companies in the technology commercialization stage — the "Death Valley" gap between preclinical work and clinical entry. This is expected to serve as a critical bridge for biotech SMEs that secured early licensing deals or seed funding but are struggling to close follow-on rounds.

Practical Fundraising Strategies for Biotech SMEs

Given this environment, biotech SMEs have three concrete strategic options.

First, actively leverage public-private cooperation channels. Platforms such as the Biohealth Investment Council bring policy finance institutions and private VCs together in joint deal sourcing, placing greater weight on technical merit and public value in due diligence than purely private rounds do. In a market skewed toward oncology, these channels offer non-oncology pipelines a fairer path to evaluation.

Second, differentiate non-oncology pipelines through strategic positioning. Rather than relying on a single indication, presenting an indication-expansion roadmap and combination-therapy data that link back to oncology applications can significantly boost investor appeal. For example, a metabolic disease therapeutic that is backed by data on managing cancer treatment side effects or potential combination use with checkpoint inhibitors can broaden its investor base.

Third, strengthen the completeness of technology commercialization plans and IR materials. A hybrid fundraising strategy that connects government R&D funding with private investment requires materials that integrate not just the clinical development plan, but also government R&D project history, patent portfolio, and regulatory strategy.

KITIM supports biotech SMEs with advisory services for IR materials and technology commercialization plans, as well as fundraising strategies that connect government R&D projects with private investment. Companies seeking pipeline differentiation strategies and fundraising roadmaps amid the current oncology-focused investment climate are welcome to contact the KITIM consulting team.

Bio Venture CapitalOncologyImmunologyVenture InvestmentBiohealth Investment Consortium

Related Posts

Bio

Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

2026-11-09
Management Consulting

Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

2026-11-09
Smart Factory

The Government Pays for the Build, You Pay to Keep It Running — Software Subscriptions and AI Model Retraining Costs Outside the 2027 Manufacturing-AI Smart Factory Support, and How SMEs Should Budget 3–5 Years of Operation Before Applying

The 2027 Manufacturing-AI Smart Factory program reportedly offers up to KRW 200 million (70% support outside the capital region), but software subscriptions and AI retraining costs fall outside its scope. This guide shows how to build a 3–5 year TCO table, negotiate vendor terms, and present an operating plan in your proposal before you apply.

2026-11-09
Updated daily

Let AI find government support programs in this field

Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

Get AI-Matched Programs for Free

Need Consulting?

Our technology innovation consultants will propose the optimal solution for your company.